Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib Combination Therapies in Advanced NSCLC with KRAS G12C Mutation
NCT05609578Phase 2Active, not recruiting
- Sponsor
- Mirati Therapeutics
- Start
- Nov 2022
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of adagrasib in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Mirati Therapeutics. Primary endpoints: Objective Response Rate at 30 months and Progression-free Survival at six months at 30 months. Started Nov 2022; status: active, not recruiting.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05609578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05609578.